Drug Trial Radar · NCT04065399
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
447
Planned (sponsor's estimate)
Start
Nov 5, 2019
Primary completion
Dec 15, 2027
Study completion Dec 15, 2027
Sponsor
- Lead sponsor
- Syndax PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Conditions
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Mixed Lineage Acute Leukemia
- Mixed Phenotype Acute Leukemia
- Acute Leukemia of Ambiguous Lineage
Interventions
revumenibDrug
revumenib orally
cobicistatDrug
Phase 1 Arm C participants will receive 150 mg cobicistat daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicities (DLTs) (Phase 1)Time frame: Approximately 1 year
- Number of participants with treatment-emergent adverse events (TEAEs) (Phase 1)Time frame: Approximately 1 year
- Cmax (Phase 1)Time frame: Approximately 1 year
- Tmax (Phase 1)Time frame: Approximately 1 year
- AUC0-t (Phase 1)Time frame: Approximately 1 year
- CR+CRh rate (Phase 2 [Cohorts 2A-2C])Time frame: Approximately 3 years
- Number of participants with TEAEs (Phase 2 [Cohorts 2A-2C])Time frame: Approximately 3 years
- Cmax (Phase 2 [Cohort 2D])Time frame: Approximately 3 years
- AUC0-tau (Phase 2 [Cohort 2D])Time frame: Approximately 3 years
Locations
57 sites in 11 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California · Active not recruiting
University Of California Care Medical Group - Norris Comprehensive Cancer Center And Hospital
Los Angeles, California · Completed
Stanford Cancer Institute
Palo Alto, California · Active not recruiting
University of Colorado
Aurora, Colorado · Recruiting
Florida Cancer Specialists and Research Institute
Sarasota, Florida · Active not recruiting
Moffitt Cancer Center
Tampa, Florida · Completed
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
Children's Healthcare of Atlanta
Atlanta, Georgia · Completed
The University of Chicago Medical Center
Chicago, Illinois · Recruiting
University of Iowa Hospital
Iowa City, Iowa · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Active not recruiting
Washington University in St. Louis School of Medicine
St Louis, Missouri · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Completed
Memorial Sloan Kettering Cancer Center
New York, New York · Active not recruiting
Montefiore Medical Center
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
University of Cincinnati
Cincinnati, Ohio · Completed
Ohio State University
Columbus, Ohio · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Active not recruiting
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah · Completed
Alfred Hospital
Melbourne, Australia · Recruiting
Sir Charles Gairdner Hospital
Nedlands, Australia · Recruiting
Royal North Shore Hospital
Saint Leonards, Australia · Recruiting
Peter MacCallum Cancer Centre (PMCC)
Melbourne, Victoria, Australia · Active not recruiting
Royal Melbourne Hospital (RMH)
Parkville, Victoria, Australia · Active not recruiting
University Health Network
Toronto, Canada · Recruiting
The Hospital for Sick Children
Toronto, Canada · Active not recruiting
Hospital Saint-Louis - APHP
Paris, France · Recruiting
Centre Hospitalier Universitaire (CHU) de Bordeaux
Pessac, France · Recruiting
Centre Hospitalier Lyon Sud
Pierre-Bénite, France · Recruiting
Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
Villejuif, France · Recruiting
Universitaetsklinikum Essen (AoR)
Essen, Germany · Withdrawn
Universitaetsmedizin Greifswald
Greifswald, Germany · Completed
Universitaetsmedizin Der Johannes
Gutenberg, Germany · Recruiting
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany · Recruiting
University of Leipzig
Leipzig, Germany · Recruiting
Klinikum Nuernberg Nord
Nuremberg, Germany · Completed
University Hospital Of Ulm, Universitatsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany · Recruiting
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.